

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>GADICKE ANSBERT</u>  (Last) (First) (Middle) C/O MPM BIOIMPACT LLC 399 BOYLSTON STREET, SUITE 1100  (Street) BOSTON MA 02116  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Aktis Oncology, Inc. [ AKTS ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 01/12/2026	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/12/2026		C		1,314,262 <sup>(1)</sup>	A	(2)	1,655,971	I	See Footnote <sup>(3)(4)</sup>
Common Stock	01/12/2026		C		5,914,197 <sup>(5)</sup>	A	(2)	7,570,168	I	See Footnote <sup>(3)(6)</sup>
Common Stock	01/12/2026		C		1,577,119 <sup>(7)</sup>	A	(2)	9,147,287	I	See Footnote <sup>(3)(8)</sup>
Common Stock	01/12/2026		P		1,112,777 <sup>(9)</sup>	A	\$18	10,260,064	I	See Footnote <sup>(3)(10)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series Seed Redeemable Convertible Preferred Stock	(2)	01/12/2026		C			5,000,000	(2)	(2)	Common Stock	1,314,262	\$0 <sup>(2)</sup>	0	I	See Footnote <sup>(1)(3)</sup>
Series A Redeemable Convertible Preferred Stock	(2)	01/12/2026		C			22,500,000	(2)	(2)	Common Stock	5,914,197	\$0 <sup>(2)</sup>	0	I	See Footnote <sup>(3)(5)</sup>
Series B Redeemable Convertible Preferred Stock	(2)	01/12/2026		C			6,000,000	(2)	(2)	Common Stock	1,577,119	\$0 <sup>(2)</sup>	0	I	See Footnote <sup>(3)(7)</sup>

1. Name and Address of Reporting Person* <u>GADICKE ANSBERT</u>  (Last) (First) (Middle) C/O MPM BIOIMPACT LLC 399 BOYLSTON STREET, SUITE 1100  (Street) BOSTON MA 02116  (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>MPM ASSET MANAGEMENT LLC</u>  (Last) (First) (Middle)

C/O MPM BIOIMPACT LLC  
399 BOYLSTON STREET, SUITE 1100

(Street)  
BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

Oncology Impact Private Investment Fund 2, L.P.

(Last) (First) (Middle)

C/O MPM BIOIMPACT LLC  
399 BOYLSTON STREET, SUITE 1100

(Street)  
BOSTON MA 02116

(City) (State) (Zip)

**Explanation of Responses:**

1. The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadick are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadick is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact.
2. Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.
3. The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
4. The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadick is the manager of MPM AM.
5. The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact.
6. The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact.
7. The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact.
8. The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact.
9. The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact.
10. The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact.

**Remarks:**

This filing is 1 of 2 identical filings due to limitations on number of Reporting Persons. See Form 4 filed by MPM BioVentures 2018, L.P.

/s/ Ansbert Gadick 01/14/2026

/s/ Ansbert Gadick, manager of  
MPM Asset Management LLC 01/14/2026

/s/ Ansbert Gadick, managing  
member of MPM Oncology  
Investments 2 LLC 01/14/2026

/s/ Ansbert Gadick, managing  
member of MPM Oncology  
Investments 2 LLC, the general  
partner of Oncology Impact  
Private Investment Fund 2, L.P. 01/14/2026

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**